Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of July 2018, with a specific reporting date of July 19, 2018. The registrant is a foreign private issuer incorporated in Belgium, headquartered in Mechelen. The filing serves to incorporate a press release (Exhibit 99.1) by reference into the company's registration statements.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.
Material Changes
The filing does not disclose specific material changes in financial position or operations within the text provided. The primary material event is the issuance of a press release on July 19, 2018, the content of which is attached as Exhibit 99.1 but not summarized in the body of this Form 6-K.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the press release includes quotes from Dr. Simon Moroney and Mr. Onno van de Stolpe, but the substance of these quotes is not included in the filing text provided.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Content Source: The substantive information regarding the July 19, 2018 event is located in Exhibit 99.1 (the press release), which is not included in the provided text.
- Financial Data: No financial metrics are available in this specific filing; investors must refer to the company's Form 20-F or other financial reports for quantitative data.
- Registration Statements: The press release is incorporated by reference into multiple Forms F-3 and S-8.